Telomere Parameters in Patients With Nonalcoholic Fatty Liver

NCT01694342 | Unknown

• 1 other identifier: ramona 1.0
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Telomerase, through its regulatory function on telomere length may play an important role in immune function, cellular replicative life span, and carcinogenesis. Non-alcoholic fatty liver disease (NAFLD) is considered a benign condition, but in some cases, it may progress to cirrhosis and hepatocellular carcinoma. The risk factors for that evolution are not fully understood. Our group showed in a previous study, that hTERT mRNA expression is lower in peripheral lymphocytes of patients with fatty liver, compared to healthy controls. This finding could explain the telomere shortening found previously in these patients by our group \[20\] and others \[21\]. Furthermore, we found higher rates of TC in these patients, probably due to an attempt to counteract the shortening of the telomeres and to stabilize them. This is through a different mechanism that is not telomerase-mediated. Telomere capture is considered an alternative way to maintain telomere length and chromosomal stability \[3\]. It is a more common mechanism for chromosome stabilization and repair, in contrast to the telomerase-mediated process of chromosome healing and elongation This study aimed to evaluate mechanisms of telomere homeostasis like telomere shortening, telomerase activity, telomere capture and aneuploidy in patients with NAFLD in order to explain previous findings of telomere shortening in these patients.

Conditions

FATTY LIVER; NO MALIGNANCY; NO DECOMPENSATED ILLNESS

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Individuals - over 18 years old that were diagnosed with nonalcoholic fatty liver and are on follow-up in our liver unit

You may qualify if:

• age over 18
• diagnosis of fatty liver

You may not qualify if:

• no malignancy
• no eligible to sign the consent paper

Sponsors & Collaborators

• Meir Medical Center: lead

Study Sites (1)

Meir Hospital

Kfar Saba, Israel

Location

MeSH Terms

Conditions

Fatty Liver

Condition Hierarchy (Ancestors)

Liver Diseases; Digestive System Diseases

Central Study Contacts

Yona Kitay-Cohen, MD

CONTACT

+97297471560; yonaki@clalit.org.il

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 23, 2012
• First Posted: September 27, 2012
• Study Start: September 1, 2012
• Last Updated: September 27, 2012

Record last verified: 2012-07

Locations

IL (1)